Discovery of false-positive target binding, due to assay interference or aggregation, presents a significant problem for drug discovery programs. These issues may often be unrealized and could lead researchers astray if not subject to independent verification of reproducibility and/or on-target mechanism of action. Although well-documented for small molecules, this issue has not been widely explored for peptide modality. As a case study, we demonstrate that two purported KRas inhibitors, stapled peptide SAH-SOS1A and macrocyclic peptide cyclorasin 9A5, exemplify false-positive molecules -both in terms of their sub-micromolar KRas binding affinities and their on-target cellular activities. We observed that the apparent binding of fluorescein-labeled SAH-SOS1A given by a fluorescence polarization assay is sensitive to detergent. False-positive readouts can arise from peptide adsorption to the surface of microplates.
Introduction
Drug discovery programs are often initiated with efforts aimed at identifying molecules that bind their targets with high affinity to modulate biological activity with high selectivity and potency. Ensuring that the binding interaction is authentic is crucial as the risk of being misled by a false positive is substantial. Indeed, examples show that misleading biological activities given by questionable compounds (1, 2) , if left unchecked, can propagate in the scientific literature (3, 4) . Consequently, there may be undesirable effects within both research and drug discovery in terms of time and investment to pursue molecules that are not true benchmarks to further investigate target-driven disease mechanisms (5-7)
Pan-assay interference (8) and colloidal aggregation (9) may underscore the basis for most frequently identified false-positive molecules. Increasing evidences have emerged in the literature to elucidate such promiscuous activities (5, 10, 11) . These non-specific and misleading activities could occur through several mechanisms (10) which include covalent reactivity, redox cycling, fluorescence interference, membrane disruption, and the formation of colloidal aggregates. Among them, colloidal aggregate formation is perhaps the most common (12, 13) . In seminal work (9) , Shoichet and colleagues proposed that the colloidal aggregates exert their effects by enzyme sequestration, thereby blocking and inhibiting their activities in unexpected ways. The lists of aggregators are not just limited to synthetic small molecules, and are also found among natural products (14) and marketed drugs (15) ; these issues are widespread.
Besides enzymes, targets involved in protein-protein interactions are affected as well (16, 17) .
Importantly, these artefacts are difficult to discern if the readout from the assay is reproducible and dose-dependent. One tool for addressing this requires the addition of detergents into the biochemical assay such that the apparent activities of colloidal aggregates can be alleviated or even completely abrogated (18) .
Macrocyclic peptides represent an exciting chemical modality with the potential to therapeutically address intracellular protein-protein interactions -these represent targets that are most often intractable with a small-molecule modality (19, 20) . Indeed, the macrocyclic peptide approach can produce molecules that exhibit highly specific one-to-one stoichiometric binding and on-target cellular activities (21, 22) . In fact, these efforts have translated to a macrocyclic peptide (ALRN-6924) that has entered clinical trials (23) . Despite these encouraging developments, we describe herein macrocyclic peptides to also have the potential of effecting false-positive modulation of protein-protein interactions. As a case study, we report evidences that a stapled peptide (SAH-SOS1A) and a macrocyclic peptide (cyclorasin 9A5), independently described as molecules that bind to KRas and inhibit its downstream pathway, are in fact falsepositive molecules, both in terms of their sub-micromolar affinities and their on-target cellular activities (24, 25) . We first reproduce the binding isotherm of SAH-SOS1A using the fluorescence polarization assay reported in the original publication (24) . However, to our surprise, adding detergent into the assay solution completely abolished binding. Further experiments suggest that the apparent binding may arise from adherence of the stapled peptide to the microplate. Additionally, using reporter-free techniques, such as surface plasmon resonance and isothermal titration calorimetry, we unambiguously showed that SAH-SOS1A and cyclorasin 9A5 did not bind to KRas. In thermal shift assay, the melting temperature of KRas decreased in the presence of the peptides as opposed to the no-ligand control, suggesting ligand-induced destabilization of the protein. This phenomenon was further confirmed by the data from hydrogen-deuterium exchange monitored using mass spectrometry. Both peptides induced more deuterium uptake relative to the no-ligand control indicative of destabilization of the protein.
Critically, we have validated these biophysical methods for KRas by employing a macrocyclic peptide (KRpep-2d) discovered by Takeda (26) as the positive control in all the assays we used.
The same group also delineated the binding of KRpep-2d with a careful study of its structuralactivity-relationships (27) and confirmed the binding with a co-crystal structure of KRpep2d/KRas (28) .
In this report, we further showed that the cellular activities of SAH-SOS1A and cyclorasin 9A5 were attributed to their ability to trigger the lysis of cell membranes at an EC50 in the range of 10−30 M as measured by the release of intracellular lactate dehydrogenase (LDH). The LDH release potencies coincidentally overlap with their reported cytotoxic potencies. Furthermore, both peptides exhibited strong anti-proliferative effects in KRas-independent cell lines, suggesting KRas is not their biological target. Collectively, we conclude that the apparent biological activities reported in both publications may arise from off-target activities and/or nonspecific cell death due to the rupture of cell membranes.
Results and Discussion
FAM-SAH-SOS1A is a Promiscuous Binder. Mutant KRas is a significant oncogenic driver (29, 30 ). Yet, KRas is typically considered a challenging therapeutic target as the surfaces that mediate the interactions between KRas and its downstream effectors lack deep hydrophobic pockets to which a small molecule might bind (31, 32) . As an alternative approach, data has supported macrocyclic peptides as a promising modality for targeting protein-protein interactions (19, 20, 33) . This prompted us to investigate two widely cited publications published in 2015 by Walensky and colleagues (24) and Pei and colleagues (25) . To disrupt the KRas−SOS1 interaction, Walensky and colleagues designed an 18-residue stapled peptide, named SAH-SOS1A, by incorporating two extra arginines at the N-terminus and an i, i+4 hydrocarbon linker at the non-interacting face of the SOS1 -helix (929-944). Using fluorescence polarization (FP) as the primary assay, the investigators showed that a fluorescein-labeled SAH-SOS1A could bind to wild-type, as well as G12D, G12C, G12V, G12S and Q61H mutated forms of KRas with apparent dissociation constants in the range of 100 to 175 nM. Their results further suggested that SAH-SOS1A engaged both GDP-and GTP-loaded wild-type KRas with indistinguishable affinities, despite the fact that these two forms of the protein are well known to adopt vastly different conformations in solution (34) .
First, we were able to reproduce the binding isotherm of fluorescein-labeled SAH-SOS1A (FAM-SAH-SOS1A) using a few selected forms of KRas (G12D, Q61H, and wild-type) loaded with GDP (Fig. 1A, Fig. S1 ). The FP binding curve adopted a sigmoidal shape and seemed saturated, despite the sub-optimal fitting (R 2 = 0.812, Fig. 1A ). To our surprise, the apparent bindings were completely abolished upon addition of non-ionic detergent (0.01% v/v Tween 20)
to the assay buffer. To check for promiscuous binding, we titrated sequence-unrelated proteins, e.g., MDM2 (Fig. 1B) and eIF4E ( Fig. 1C) separately, into FAM-SAH-SOS1A. Further confirming the non-specific nature of the signal, FAM-SAH-SOS1A demonstrated apparent binding to each of these unrelated target proteins with affinities similar to that obtained for KRas.
Similarly, these binding interactions were found to be detergent-sensitive. We also tested the negative control peptide (FAM-SAH-SOS1B), which has a hydrocarbon linker installed at the interacting face of the helix. FAM-SAH-SOS1B showed no binding in the FP assay as described in the publication (24) . However, we found that FAM-SAH-SOS1B could bind to KRas as well as the unrelated proteins, albeit the signal increases were lower in magnitude (Fig. S2) (i) FAM-labeled peptide non-specifically adsorbs on to the plastic surface of the microplate, and/or (ii) FAM-labeled peptide forms a colloidal aggregate which then sequesters the proteins.
Under both circumstances, the apparent "hydrodynamic size" of the peptide increases, leading to a slower tumbling rate and an increased fraction of polarized light. As a result, the FP signals increase and give a false impression that the peptide binds, one-to-one, to a protein.
To test whether the microplate could influence the assay, we explored three different types of microplates: (i) uncoated polypropylene microplate (used for the experiments in Fig. 1 and Fig.   S1 and S2); (ii) uncoated polystyrene microplate; and (iii) polystyrene microplate coated with a non-ionic hydrophilic material (Corning NBS TM ). We observed apparent binding of FAM-SAH-SOS1A regardless of the use of polystyrene or polypropylene microplate ( Fig. 2A and 2B ). The apparent binding disappears once we added the detergent or switched to a polystyrene microplate with a non-binding surface (Fig. 2C) . Thus, it appeared that the increased FP signal was related to non-specific adherence of FAM-SAH-SOS1A to the plastic surface or protein-coated plastic surface rather than a specific biomolecular interaction with KRas. Indeed, the degree of absorption is minimal for a microplate of hydrophilic nature, with or without the detergent (Fig.   2C ). Although the amount of KRas protein added to the sample did increase the magnitude of the FP signal, we are confident that this effect is non-specific. This is backed by two observations. (Fig. S4A ) than in an uncoated polypropylene microplate (Fig. S4B ). This is not surprising because the polystyrene surface is generally more hydrophobic than the polypropylene surface (35) . In contrast, the FP signal remained flat for the coated polystyrene microplate (Corning NBS TM ) regardless of the incubation time or the concentration of peptide used (Fig. S4C ). All data above, thus far, support our hypothesis that adsorption of FAM-labeled peptide to the plastic surface is responsible for the apparent binding observed in the FP assays.
Detection of Aggregators by Dynamic Light Scattering. Alternatively, FAM-labeled peptides may form colloidal aggregates which can sequester proteins, therefore giving a false-positive FP readout. Assay interference due to aggregation is usually time-and concentration-dependent (9), and the readouts are sensitive to detergent (18) . To characterize the peptides, we employed dynamic light scattering (DLS) as a universal technique to directly monitor aggregation. We observed strong and well-defined autocorrelation functions which suggest aggregation in 10 M solution of FAM-SAH-SOS1A and FAM-SAH-SOS1B (Fig. 3 ). Both peptides gave strong scattering intensities (5700−7400 kcps for FAM-SAH-SOS1A and 12600−14500 kcps for FAM-SAH-SOS1B), whereas the signal is much lower for the buffer alone (35−36 kcps). The hydrodynamic diameters of the particles range from 350 to 370 nm for FAM-SAH-SOS1A and 1200 to 1600 nm for FAM-SAH-SOS1B. However, we could not detect reproducible and welldefined DLS signals for SAH-SOS1A, SAH-SOS1B and cyclorasin 9A5 (data not shown). There are either no aggregates or the aggregates are not stable for these label-free peptides at the concentration tested (10 M). Interestingly, the ATSP-7041 (A 8 Q, Q 9 L) showed aggregation at 10 M (Fig. S5 ), yet it was a specific inhibitor of MDM2 when used at a much lower concentration (<100 nM, Fig. 4 ). It is noted that, at the tested concentration of 10 M, it is insufficient to conclude that aggregates are responsible for the false-positive FP readout. We conclude that this most likely derives from direct binding of the peptide to the plastic surface of the microplate.
Surface Plasmon Resonance Confirms SAH-SOS1A and Cyclorasin 9A5 as Non-binders for
KRas. To carry out a more rigorous analysis, we perceived that it was crucial to run the putative peptides through an orthogonal binding assay, ideally an alternative reporter or reporter-free technique, to ensure that the activity measured by the primary assay is genuine and targetdependent. As a result, we employed surface plasmon resonance (SPR) as the first-pass orthogonal assay. SPR is a reporter-free technique that monitors the association and dissociation of biomolecules in real time. It provides insights into the stoichiometry and reversibility of the binding across a range of concentrations. Consistent with our results from the FP assays, we found no binding at all for SAH-SOS1A and cyclorasin 9A5, up to 1 M, across the flow cell containing KRas G12D (Fig. 4 , top row). These results implied that either their dissociation constants (KD) are much greater than 1 M or they simply are non-binders. Similarly, FAM-SAH-SOS1A also did not bind to KRas G12D as demonstrated by SPR (Fig. S6 ). To ensure that
KRas immobilized on the biosensor is competently-folded and functional, we used KRpep-2d, a macrocyclic peptide discovered by Takeda through phage display (26) , as the positive control.
Indeed, KRpep-2d could bind to KRas G12D and the binding responses are saturable (Fig. S7 ).
Paradoxically, we observed significant SPR readouts from the flow cells immobilized with MDM2 or eIF4E, when we tested SAH-SOS1A ( It is unclear how SAH-SOS1A and cyclorasin 9A5 interact with MDM2 and eIF4E.
Previously, SPR has been demonstrated to recognize aggregates quite early in the discovery process (36) . It is rather sensitive to non-specific interactions. Adsorption of the aggregates on to the surfaces of biosensors, even though small in amount, can result in non-stoichiometric binding and amplify the SPR signal in an unexpected way (36) . We postulate that the non-saturable SPR binding responses plus the high bulk shifts probably result from the non-specific adsorption of SAH-SOS1A and cyclorasin 9A5 to the surface-loaded proteins. In contrast, ATSP-7041 (A 8 Q, Q 9 L) binds only to MDM2 but not KRas and eIF4E (Fig. 4) . PHAGESOL, a peptide we discovered previously through phage display (37) , binds exclusively to its target eIF4E but not KRas and MDM2 (Fig. 4) SAH-SOS1A and cyclorasin 9A5 did not bind to KRas G12D using ITC ( Fig. 5A and Fig. 5C ).
The heat released during the titration of SAH-SOS1A to the protein or to the buffer itself are almost identical ( Fig. 5A and Fig. 5B ). Importantly, cyclorasin 9A5 did not bind to KRas G12V which was the protein reported for the original discovery of the macrocyclic peptide (Fig. 5D ).
To demonstrate that the KRas used for ITC is well-folded, we showed that the positive control (KRpep-2d) binds to KRas G12D with a KD of 21 nM and a stoichiometry close to unity (Fig.   5E , stoichiometry of 0.625 indicates not all the KRas protein is well folded). It is well known that wild-type KRas adopts distinct conformations and functions when bound to different nucleotides. As a confirmatory experiment, we show that wild-type KRas binds to its downstream effector (Raf-RBD) only when KRas is activated with GMPPNP (KD = 6 nM, N = 0.554) but not with GDP ( Fig. 5F and 5G).
We also performed thermal shift assays for SAH-SOS1A and cyclorasin 9A5. Both peptides produced a negative shift in the melting temperatures (Tm) of KRas G12D (Fig. S8) , as compared to the no-ligand control, indicating ligand-induced destabilization. At higher concentrations, SAH-SOS1A displayed high initial background probably due to aggregated peptide-dye interactions (Fig. S8A ). Furthermore, a global service partner (Proteros) also failed to detect binding of either peptide with crystal-grade protein using ITC and thermal shift assay (data not shown). As an important positive control, KRpep-2d was able to stabilize KRas with a significant positive Tm of +11.5 °C (Fig. S8C) , indicating a well-folded protein capable of binding to specific ligands. To ensure our biophysical observations were not unique to cyclorasin 9A5, we tested a closely related analog, cyclorasin 9A16, a molecule with reported IC50 values that were similar to cyclorasin 9A5's in both the inhibition of KRas-Raf interaction and antiproliferative assay (25) . Once again, the thermal shift assay produced a negative Tm shift (-5.9
C) for cyclorasin 9A16 (Fig. S9A) . By employing SPR and ITC experiments, we further validated cyclorasin 9A16 as a non-binder, i.e., false positive, for KRas ( Fig. S9B and S9C ). to faithfully map the peptide-binding sites (Fig 6) . In contrast, the experiments involving SAH-SOS1A, cyclorasin (9A5 and 9A16) demonstrated a complete absence of specific binding and agreed well with the destabilization (Fig. 6E ) observed in the thermal shift assay (Fig. S8 and   S9A ). Specifically, the HDX-MS data suggest non-specific and protein-wide destabilization of KRas G12D in the presence of SAH-SOS1A, cyclorasin (9A5 and 9A16) (Fig 6A−C) . All three peptides showed similar deuterium uptake profiles suggestive of similar effects on KRAS G12D.
HDX-MS
In addition, no significant binding-induced protection from deuterium uptake was observed at any pepsin-proteolyzed KRas G12D peptides, which confirms the absence of binding of SAH-SOS1A, cyclorasin (9A5 and 9A16) to KRas G12D. HDX experiments monitoring binding of positive control peptide to KRas G12D showed protection from deuterium uptake at regions previously identified as binding site for KRpep-2d from X-ray structural studies ( Fig. 6D and 6F ) (28) . Together, these results confirm that solution dynamic analysis (using deuterium labeling (24) were designed and docked to the structure of Ras complexed to SOS. These peptides were subject to MD simulations to monitor their stability (Fig. S11) . None of the peptides (unstapled and stapled) were found to remain in the initial (and speculated) location and were observed to drift away; this agreed with the experimental observations that none of the peptides bind to KRas. In a similar manner, the complexes between KRas and cyclorasin 9A5 were generated and subject to MD simulations. Once again, the peptides did not bind stably and drifted away ( KRas, we were perplexed by the biological activities reported in the publications (24, 25) .
Release of intracellular lactate dehydrogenase (LDH) is a common method used to directly quantify the degree of cell membrane rupture. We could detect appreciable LDH leakage for SAH-SOS1A (EC50 = 10 M), SAH-SOS1A with unstapled hydrocarbon (EC50 = 8 M) and cyclorasin 9A5 (EC50 = 30 M) (Fig. 7) . The EC50 of LDH leakage for these peptides is comparable to the EC50 of the positive control (iDNA79, EC50 = 20 M). iDNA79 is a cationic amphipathic stapled peptide we discovered in-house that gave strong lytic activity. In contrast, the LDH release is insignificant (< 10%) for SAH-SOS1B, Aib-SOS1A, cyclorasin 12A, ATSP-7041 (A 8 Q, Q 9 L) and PHAGESOL, and minimal (< 30%) for cyclorasin 9A54, up to 50 M of the concentration tested.
We performed the LDH release assay using HCT116, a colorectal cell line which harbors mutant KRas
G13D
, under serum-free condition. Although serum could influence the assay, we believe the condition is relevant because the viability assay reported in the publication (24) is performed under serum-free condition during the peptide treatment. We incubated the cells with peptides for 4 hours. We expect that rapid cell death within this short treatment time is unlikely to involve cell cycle arrest and apoptosis due to the inhibition of KRas signaling pathway. The rupture of plasma membrane, a hallmark of non-specific cell death, is most likely the cause. The LDH results suggest that SAH-SOS1A and cyclorasin 9A5, when used at sufficiently high concentration (10-30 M), may have compromised the plasma membrane, and caused the lysis and rapid death of cells. Interestingly, these undesired toxicities are only observed for SAH-SOS1A and its unstapled hydrocarbon analog, but not for its linear version (Aib-SOS1A), and the negative control (SAH-SOS1B) where the stapled hydrocarbon is placed at a different face of the helix. Minimal LDH leakage is also observed for the analogs of cyclorasin 9A5, such as cyclorasin 9A54 and cyclorasin 12A. Coincidentally, the degree of membrane disruption caused by the SAH-SOS1A, cyclorasin 9A5 and their non-toxic analogs is consistent with the cytotoxicity reported in the publications (24, 25) . In a different report, Bird et al. disclosed that SAH-SOS1A did not induce LDH release (38) . But, we found that the tested peptides are actually different from the original SAH-SOS1A (24) . The investigators changed the length of the hydrocarbon staple and removed the two arginine residues from SAH-SOS1A that could be accountable for the membrane disruption.
SAH-SOS1A and Cyclorasin 9A5 Exhibit Off-target Cytotoxic Activities in KRas-
independent Cell Lines. To further investigate the promiscuous cellular activities, we assessed the effects of SAH-SOS1A and cyclorasin 9A5 on the proliferation of KRas-independent cell
lines (U-2 OS cells and A549 cells). These cell lines do not require KRas to maintain viability and their downstream signaling is not responsive to KRas knockdown by gene silencing (39, 40).
Strikingly, above a concentration threshold of 20 M, we observed strong anti-proliferative effects of SAH-SOS1A and cyclorasin 9A5 on both cell lines (Fig. 8A) . The results suggest that both peptides act through off-target mechanisms, since inhibition of the KRas signaling pathways should not impede the proliferation of these cells. We also note that the dose-response curves are very steep, i.e., a small increment of peptide concentration (< 6-fold change) is enough to induce a strong anti-proliferative effect (a decrease from plateau to baseline level).
We further investigated the effect of the peptides on the KRas signaling pathways using U-2 OS cells (Fig. 8B) . We showed that SAH-SOS1A but not cyclorasin 9A5 could inhibit the 
Concluding Remarks
FP assay is by far the most popular technique (41) for validating protein-protein interactions.
Its advantages of high-throughput, mix-and-read format, and the relatively low demand of proteins, makes its cost lower when compared to other techniques. When using a well-validated probe, competitive FP assay is a powerful primary screen for a large library of compounds.
However, we showed that direct binding FP assay could be prone to false-positive results. In this report, we demonstrated that fluorescein-labeled peptides gave a false impression of "binding" in FP assay when detergent is omitted in the assay buffer. This is most likely derived from the adherence of the peptide to the plastic surface or protein-coated plastic surface. Such assay interference could mislead the interpretation and are difficult to discern. By employing SPR and ITC as the reporter-free assays, we unambiguously showed that SAH-SOS1A and cyclorasin Finally, we showed that SAH-SOS1A and cyclorasin 9A5 triggered LDH release by disrupting the cell membrane. Amphipathic peptides with positive charges at one face and hydrophobic patch at the other tend to disrupt cell membranes and cause non-specific cytotoxicity (45, 46) . Both SAH-SOS1A and cyclorasin 9A5 contain excessive hydrophobic moiety and multiple positively charged residues. However, such observations cannot be generalized as the closely related analogs of SAH-SOS1A and cyclorasin 9A5 did not induce significant LDH release. Moreover, we observed strong anti-proliferative activities of SAH-SOS1A and cyclorasin 9A5 for KRas-independent cell lines. Collectively, we deduce that SAH-SOS1A and cyclorasin 9A5 most likely killed cancer cells, through off-target effects by the disruption of the cell membrane, rather than through the intended attenuation of signaling pathways mediated by KRas. More work is required to elucidate these off-target activities, such as their mechanisms and structural-activity-relationships which is beyond the scope of this report (47) . Yet, we note that by improving the physicochemical properties of SAH-SOS1A and cyclorasin 9A5, these molecules may become a template useful for binding to their target and for further cellular studies.
Though this report has focused on KRas, our approaches to characterize the macrocyclic peptides are also applicable to other target classes involved in protein-protein interactions (Fig.   9 ). Our findings make a strong case for using reporter-free systems such as SPR and ITC, whenever possible, as a secondary assay for binding validation. SPR is very sensitive to nonspecific binding. Non-saturable SPR signals could imply aggregation or some arcane activity (36) . In such cases, ITC should be employed instead to ensure getting the ideal 1:1 stoichiometric binding. We acknowledge that SPR and ITC are low in throughput. These methods might not be suitable for the primary screen performed on a routine basis. Yet, they should be used more often, at least, for the most promising lead, in order to ensure that binding is genuine and the stoichiometry is as expected. We also suggest LDH release assay as a convenient counter-screen to ensure that the observed biological activities do not arise from membrane disruption. In contrast to cell viability assays or indirect measurement of downstream cellular responses, direct intracellular target engagement assays are better tools to prove that the desired target is actually bound when cells are treated with the compounds (Fig. 9 ). For instance, CETSA (48) and NanoBRET (49) are increasingly employed to distinguish on-target versus offtarget cancer-killing effects. We hope that, by adopting these measures frequently, it will de-risk assay interference, reveal promiscuous target-unrelated activity, thereby improving the quality of publications to promote a sustainable future for science. Reproducibility does count and orthogonal reporter-free assays should be an essential component of any claim of specific protein-peptide interactions measured by a screening assay based on a fluorescent reporter.
Collectively, multiple lines of evidence will serve to strengthen the robustness of the claim.
Materials and Methods
SAH-SOS1A and its related analogs were synthesized in house. Cyclorasin 9A5 and its related analogs were sourced from CPC Scientific and IRBM Science Park. ATSP-7041 (A 8 Q, Q 9 L) was synthesized in house. PHAGESOL was synthesized by Mimotopes Pty Ltd. The sequences of the peptides used in this study and their observed m/z could be found in Table S1 . All peptides are dissolved in neat DMSO as 10 mM stock solution and diluted thereof for subsequent experiments. Complete descriptions of peptide synthesis, protein expression, biotinylation of protein by sortase ligation, fluorescence polarization assay, dynamic light scattering, surface plasmon resonance, isothermal titration calorimetry, thermal shift assay, hydrogen-deuterium exchange mass spectrometry, molecular simulations, lactate dehydrogenase release assay, cellular growth assay and western blotting are provided in SI Methods. However, the bindings were abolished or attenuated in the presence of detergent. Data are mean of technical triplicates ± SD. R 2 corresponds to the fitting of no-detergent data (solid circle). 
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Materials and Methods
Peptide synthesis. Peptides were synthesized in-house using the 9-fluorenylmethyloxycarbonyl (Fmoc) solid-phase peptide synthesis (SPPS) method at the 0.1 mmol scale using H-Ramage-Chemmatrix resin (0.53 mmol g -1 ) obtained from PCAS-Biomatrix (Quebec, Canada). All amino acids were purchased from either Advanced Chemtech (Louisville, KY) or Okeanos Tech. Co. Ltd (China). All other solvents and reagents were obtained from Advanced Chemtech (Louisville, KY) or Sigma-Aldrich. All amino acids were N-Fmoc protected and side chains were protected with Boc (Lys, Trp); OtBu (Ser, Thr); Trt (Cys, Asn, Gln). The peptides were synthesized either manually or through the use of a microwave assisted automated peptide synthesizer (CEM-Liberty Blue).
Method A: Manual synthesis of peptides
The dry resin was swollen with NMP before use. Deprotection was performed with 20% piperidine in DMF (15 min). Coupling reactions were performed using pre-activated (7 min) solutions of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU, 3.9 eq), 1-hydroxy-7-azabenzotriazole (HOAt, 4 eq) and DIPEA (8 eq) in NMP (0.5 M). The coupling time was 60 min for all amino acids except for (S)-N-Fmoc-2-(4'-pentenyl)alanine and (R)-N-Fmoc-2-(7'-octenyl)alanine, which were coupled (3 eq) for 2 hours. After each coupling and deprotection reaction, the resin was thoroughly washed with DMF (5 x 1 min). The amino acids immediately following Fmoc-R8-OH and Fmoc-S5-OH were double coupled. Olefin metathesis reaction was performed on N-terminal Fmoc-or Acetyl-peptides on solid support. The resin was swollen in DCE (pre-dried and degassed) and treated with 6 mM solution of Grubbs' firstgeneration catalyst in DCE (2 h). Typically, 3-4 rounds of olefin metathesis treatments were required.
Method B: Automated synthesis of peptides
Cleavage of the peptide from the dried resin was achieved using a TFA cocktail consisting of TFA:triisopropylsilane:water (95:2.5:2.5, 8 mL) followed by filtration and precipitation with diethyl ether. The precipitate was collected by centrifugation and dried. The peptide was purified by Reverse Phase HighPerformance Liquid Chromatography (RP-HPLC) on GX-271 (Gilson), using a Phenomenex Jupiter C12, 4 μm Proteo 90 Å column (250 x 10 mm). Peptide molecular weight was confirmed by LCMS (Table S1 ).
Protein expression. Full-length human eIF4E was expressed and purified as described previously (1) . GGG-MDM2 1-125 was expressed and purified by NTU protein production platform (Singapore). KRas wildtype, G12D, G12V or Q61H were expressed, purified, and loaded with the desired nucleotide by Evotec AG (Germany).
Biotinylation of protein.
To attach biotin site-specifically to the protein, we use sortase-mediated ligation. All proteins contain at least one extra glycine at the N-terminus. The ligation was carried out with the protein target (50 M), sortaseA 61-206/8M (1 M), and biotin-KGGGLPET-GG-OHse(Ac)-amide (200 M) in 200 L of ligation buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1 mM TCEP). SortaseA 61-206/8M contains mutations that increase ligation efficiency (2) and make it calcium-independent (3). The ligation was incubated at room temperature for 4 hours. The sortase which contains a C-terminal 6His-tag was removed with Dynabeads His-Tag (cat# 10104D, Thermo Fisher). The biotinylated protein was dialyzed at 4 °C using slide-A-Lyzer cassette (10k MWCO) against 2 L of an appropriate buffer. The buffer was changed after 4−5 hours and the dialysis was repeated for overnight. The biotinylated protein was aliquoted, snapfrozen with liquid nitrogen, and stored at -80 °C.
Fluorescence polarization assay. All assays were performed at room temperature using assay buffer (50 mM Tris pH 7.4, 150 mM NaCl, 2 mM MgCl2 with or without 0.01% v/v Tween 20) and Corning (cat# 3356) 96-well black polypropylene microplate, unless otherwise stated. For experiments performed on uncoated or coated polystyrene microplate, we used Nunc (cat# 237107) 96-well black uncoated polystyrene microplate or Corning (NBS TM , cat# 3991) 96-well black coated polystyrene microplate, respectively. The protein was first diluted (2-fold serial dilution) with the assay buffer on the microplate to have a volume of 25 L in each well. This was followed by the addition of 25 L of FAM-SAH-SOS1A (30 nM, dissolved in assay buffer) to each well with multichannel pipette. The final assay solution (50 L) contains 15 nM of the FAM-SAH-SOS1A and protein (4.9 nM to 10 M). Right after the mixing, the microplate was read with EnVision 2104 Multilabel Reader (PerkinElmer) using excitation and emission wavelengths of 480 nm and 535 nm, respectively. The fluorescence anisotropy is plotted against the concentration of protein and the data was fitted with the equation below: A is the measured anisotropy, Af is the anisotropy for the free peptide (minimum of curve), Ab is the anisotropy for the fully bound peptide (maximum of curve), KD is the dissociation constant, LT is the total concentration of the peptide, PT is the total concentration of the protein.
Dynamic light scattering. Peptide (10 mM in neat DMSO) was diluted to 10 M with syringe-filtered (0.22 m) assay buffer (50 mM Tris pH 7.4, 150 mM NaCl, 2 mM MgCl2). The solution was analyzed on Zetasizer APS (Malvern Instruments) with 60 mW diode laser (830 nm) at a scattering angle of 90. The average hydrodynamic diameter of the aggregate represents the intensity-weighted mean derived from a cumulant analysis of the measured correlation curve. Each peptide was analyzed by three independent measurements at 25 C. Values of the derived count rate (kilo counts per second, kcps) and the average diameter (nm) were reported as a range from the triplicate measurements.
Surface plasmon resonance. SPR experiments were performed with Biacore T100 (GE Healthcare) at 25 C. The site-specific mono-biotinylated proteins were prepared by sortase-mediated ligation (see above). SPR buffer consisted of 50 mM Tris pH 7.4, 150 mM NaCl, 2 mM MgCl2, 10 M GDP, 1 mM DTT, 0.01% Tween 20, and 3% DMSO. For SPR study of KRpep-2d and its analog, the reducing agent (DTT) is omitted in the buffer to preserve the disulfide bond in the peptide. The CM5 chip was first conditioned with 100 mM HCl, followed by 0.1% SDS, 50 mM NaOH and then water, all performed twice with 6 sec injection at a flow rate of 100 L/min. With the flow rate set to 10 L/min, streptavidin (S4762, Sigma-Aldrich) was immobilized on the conditioned chip through amine coupling as described in the Biacore manual. Excess protein was removed by 30 sec injection of the wash solution (50 mM NaOH + 1 M NaCl) for at least 8 times. The immobilized levels are typically 2500−2800 RU. The biotinylated proteins were captured to the streptavidin, immobilized on independent flow cell, to a level of ~400 RU for KRas G12D, ~1200 RU for MDM2, and ~1600 RU for eIF4E. Flow cell consisted of only streptavidin was used as the reference surface. Using a flow rate of 30 L/min, peptides dissolved in the SPR buffer are injected for 180 sec. The dissociation was monitored for 300 sec. Each peptide injection is followed by a similar injection of SPR buffer to allow the surface to be fully regenerated. After the run, responses from the target protein surface are transformed by (i) correcting with DMSO calibration curve, (ii) subtracting the responses obtained from the reference surface, and (iii) subtracting the responses of buffer injections from those of peptide injections. The last step is known as double referencing which corrects the systematic artefacts. The resulting responses were subjected to kinetic analysis by global fitting with 1:1 binding model.
